These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22802252)

  • 1. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.
    Mascio CT; Mortin LI; Howland KT; Van Praagh AD; Zhang S; Arya A; Chuong CL; Kang C; Li T; Silverman JA
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5023-30. PubMed ID: 22802252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
    Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium.
    Mascio CT; Chesnel L; Thorne G; Silverman JA
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3976-82. PubMed ID: 24798273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
    Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
    Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.
    Snydman DR; Jacobus NV; McDermott LA
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3448-52. PubMed ID: 22391542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.
    Alam MZ; Wu X; Mascio C; Chesnel L; Hurdle JG
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5165-70. PubMed ID: 26055381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of LFF571 in a hamster model of Clostridium difficile infection.
    Trzasko A; Leeds JA; Praestgaard J; Lamarche MJ; McKenney D
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4459-62. PubMed ID: 22644020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
    Yin N; Li J; He Y; Herradura P; Pearson A; Mesleh MF; Mascio CT; Howland K; Steenbergen J; Thorne GM; Citron D; Van Praagh AD; Mortin LI; Keith D; Silverman J; Metcalf C
    J Med Chem; 2015 Jun; 58(12):5137-42. PubMed ID: 25993059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile.
    Swanson RN; Hardy DJ; Shipkowitz NL; Hanson CW; Ramer NC; Fernandes PB; Clement JJ
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1108-11. PubMed ID: 1929250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of surotomycin on Clostridium difficile viability and toxin production in vitro.
    Bouillaut L; McBride S; Sorg JA; Schmidt DJ; Suarez JM; Tzipori S; Mascio C; Chesnel L; Sonenshein AL
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4199-205. PubMed ID: 25941230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sub-lethal doses of surotomycin and vancomycin have similar effects on Clostridium difficile virulence factor production in vitro.
    Aldape MJ; Rice SN; Field KP; Bryant AE; Stevens DL
    J Med Microbiol; 2018 Dec; 67(12):1689-1697. PubMed ID: 30307842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.
    Anton PM; O'Brien M; Kokkotou E; Eisenstein B; Michaelis A; Rothstein D; Paraschos S; Kelly CP; Pothoulakis C
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3975-9. PubMed ID: 15388461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.
    Adams HM; Li X; Mascio C; Chesnel L; Palmer KL
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4139-47. PubMed ID: 25941217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
    James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS
    J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo assessment of SMT19969 in a hamster model of clostridium difficile infection.
    Weiss W; Pulse M; Vickers R
    Antimicrob Agents Chemother; 2014 Oct; 58(10):5714-8. PubMed ID: 25022586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and development of surotomycin for the treatment of Clostridium difficile.
    Knight-Connoni V; Mascio C; Chesnel L; Silverman J
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):195-204. PubMed ID: 26670919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo activities of nitazoxanide against Clostridium difficile.
    McVay CS; Rolfe RD
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2254-8. PubMed ID: 10952564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
    Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Clostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032.
    Dong MY; Chang TW; Gorbach SL
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1135-6. PubMed ID: 2821892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.